Founded in 1970 and listed on the Shanghai Stock Exchange in 2000, Hengrui Medicine is an innovative international pharmaceutical enterprise focusing on the research, development, production and promotion of high-quality drugs, focusing on the research and development of new drugs in the fields of anti-tumor, metabolic diseases, autoimmune diseases, respiratory diseases, neurological diseases and other areas, and it is one of the most innovative pharmaceutical leading enterprises in China.

The Chinese Academy of Sciences (CAS) has put forward the concept of building a national innovation system, and has successively implemented the Knowledge Innovation Project, Innovation 2020, the Pioneering Action Program and the Outline of Comprehensive and Deepening Reform, and put forward strategic research reports, such as “Embracing the Age of Knowledge Economy, and Building a National Innovation System Innovation for Development, Science and Technology Leading the Future, Innovation 2050: Science and Technology and China's Future, New Situation of Scientific and Technological Development and Strategic Choices for 2020, and other strategic research reports.

Bristol-Myers is a global biotechnology company focused on the development and commercialization of innovative, affordable antineoplastic drugs with the goal of improving treatment outcomes and access to medicines for patients worldwide.

Shanghai Medicilon Biopharmaceuticals Co., Ltd. is a drug discovery and development outsourcing service company (CRO), which has established a comprehensive technical service platform in Shanghai in line with international standards, integrating compound synthesis, compound activity screening, structural biology,** chemical evaluation, pharmacokinetic evaluation, toxicology evaluation, formulation studies and new drug registration, and has been recognized by international drug regulatory authorities. MediSipia Pharmaceutical Technology (Shanghai) Co., Ltd. was founded in February 2008, focusing on preclinical pharmacokinetic and safety evaluation studies. MediSipia's animal testing facilities are accredited by AAALAC (Association for the Assessment and Accreditation of Animals International) and the China Food and Drug Administration GLP certificate, and have met the U.S. Food and Drug Administration GLP standards. Medicilon helps clients reach their goals faster with efficient and cost-effective one-stop professional services. Close